Research Article Details
| Article ID: | A22016 |
| PMID: | 24887549 |
| Source: | Int J Biol Macromol |
| Title: | Hypoglycemic and hepatoprotective effects of polysaccharides from Artemisia sphaerocephala Krasch seeds. |
| Abstract: | Intake of dietary high fructose (HF) exerts a number of adverse metabolic effects. The present study was to investigate whether Artemisia sphaerocephala Krasch seed polysaccharides (ASKP) alleviated hyperglycemia, hepatic steatosis and oxidative injury in mice fed HF water. After 8 weeks of the experiment, administration of ASKP at 400 and 800mg/kgbw significantly reduced the fasting serum glucose, insulin concentrations and the homeostasis model assessment of basal insulin resistance (HOMA-IR) of the mice fed 20% HF water. In the oral glucose tolerance test, the administration of ASKP at 400 and 800mg/kgbw had a reduced plasma glucose concentrations after 15min of glucose loading in HF-fed mice, indicating that ASKP improved glucose intolerance. ASKP also remarkably ameliorated the HF-induced elevation of liver lipid contents and oxidative injury in mice, and caused the reduction of liver lipid peroxidation and the elevation of hepatic antioxidant system. Histopathology of the liver by conventional H&E and Oil Red O staining confirmed the liver steatosis and oxidative injury induced by HF diet and the hepatoprotective effect of ASKP. This is the first report showing that ASKP can ameliorate the high fructose-induced hyperglycemia, hepatic steatosis and oxidative injury. |
| DOI: | 10.1016/j.ijbiomac.2014.05.064 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S04 | Anti-oxidative stress | oxidative stress | α-tocopherol: antioxidant | Vitamin E | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D142 | Fructose | Chemical drug | DB04173 | -- | Intravenous nutrition drug | Under clinical trials | Details |
| D018 | Aspirin | Chemical drug | DB00945 | AKR1C1 inhibitor; PCNA downregulator | Enhance lipid metabolism | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |